BUSINESS COMBINATIONS (Details 9)	12 Months Ended			1 Months Ended		3 Months Ended	12 Months Ended						12 Months Ended
	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)	May 31, 2012 Pharma Swiss USD ($)	May 31, 2012 Pharma Swiss EUR (€)	Mar. 31, 2011 Pharma Swiss USD ($)	Dec. 31, 2012 Pharma Swiss item	Dec. 31, 2011 Pharma Swiss USD ($)	Mar. 31, 2011 Pharma Swiss EUR (€)	Mar. 10, 2011 Pharma Swiss USD ($)	Mar. 10, 2011 Pharma Swiss EUR (€)	Feb. 28, 2011 Pharma Swiss EUR (€)	Dec. 31, 2012 Pharma Swiss Partner relationships	Dec. 31, 2012 Pharma Swiss Product brands	Mar. 10, 2011 Pharma Swiss Amounts Recognized as of Acquisition Date (as previously reported) USD ($)	Mar. 10, 2011 Pharma Swiss Amounts Recognized as of Acquisition Date (as previously reported) Partner relationships USD ($)	Mar. 10, 2011 Pharma Swiss Amounts Recognized as of Acquisition Date (as previously reported) Product brands USD ($)	Dec. 31, 2011 Pharma Swiss Measurement Period Adjustments USD ($)	Dec. 31, 2011 Pharma Swiss Measurement Period Adjustments Product brands USD ($)	Dec. 31, 2011 Pharma Swiss Amounts Recognized (as adjusted) USD ($)	Dec. 31, 2011 Pharma Swiss Amounts Recognized (as adjusted) Partner relationships USD ($)	Dec. 31, 2011 Pharma Swiss Amounts Recognized (as adjusted) Product brands USD ($)
Business Combinations
Cash consideration										$ 491,200,000	€ 353,100,000
Maximum contingent payment										41,700,000	30,000,000
Fair value of contingent payments										27,500,000
Acquisition-related contingent consideration	(5,266,000)	(10,986,000)						13,200,000
Contingent consideration payment				12,400,000	10,000,000
Notional amount of foreign currency forward-exchange contract purchased												130,000,000
Gain on settlement of foreign currency forward-exchange contract						5,100,000
Foreign exchange loss recognized on amount bought to finance business acquisition						2,400,000
Remaining foreign currency consideration used to finance transaction of business combination									220,000,000
Net foreign exchange gain recognized in earnings	19,721,000	26,551,000	574,000			2,700,000
Number of therapeutic areas in which broad product portfolio is offered							7
Number of countries of operation							19
Assets acquired and liabilities assumed
Cash and cash equivalents															43,940,000					43,940,000
Accounts receivable															63,509,000			(1,880,000)		61,629,000
Inventories															72,144,000			(1,825,000)		70,319,000
Other current assets															14,429,000					14,429,000
Property, plant and equipment															9,737,000					9,737,000
Identifiable intangible assets															202,071,000	130,183,000	71,888,000	7,169,000	7,169,000	209,240,000	130,183,000	79,057,000
Other non-current assets															3,122,000					3,122,000
Current liabilities															(46,866,000)			826,000		(46,040,000)
Deferred income taxes, net															(18,176,000)			11,568,000		(6,608,000)
Other non-current liabilities															(720,000)					(720,000)
Total identifiable net assets															343,190,000			15,858,000		359,048,000
Goodwill															171,105,000			(11,445,000)		159,660,000
Total fair value of consideration transferred															514,295,000			4,413,000		518,708,000
Fair value of trade accounts receivable acquired										61,600,000
Gross contractual amount of trade accounts receivable acquired										66,800,000
Expected uncollectible of trade accounts receivable acquired										5,200,000
Entry to record inventory at its estimated fair value										$ 18,200,000
Estimated weighted-average useful life							7 years						7 years	9 years